FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892013171> ?p ?o ?g. }

• W2892013171 endingPage "101042831879925" @default.
• W2892013171 startingPage "101042831879925" @default.
• W2892013171 abstract "Lymph node metastasis is the most important prognostic characteristic of colorectal cancer. Carcinoembryonic antigen messenger RNA was shown to detect tumor cells that have disseminated to lymph nodes of colorectal cancer patients and to be at least as good as the hematoxylin and eosin method to predict survival in colorectal cancer patients. CXCL17 was recently shown to be ectopically expressed in colon cancer tumors. Therefore, CXCL17 may serve as prognostic marker alone or in combination with carcinoembryonic antigen. CXCL17 and carcinoembryonic antigen messenger RNA levels were determined using quantitative reverse transcription polymerase chain reaction with RNA copy standard in 389 lymph nodes of 120 colon cancer patients (stages I–IV) and 67 lymph nodes of 12 control patients with inflammatory bowel disease as well as in 68 primary tumors and 30 normal colon tissue samples. Lymph nodes of colon cancer patients were analyzed for CXCL17 and carcinoembryonic antigen protein expression by immunohistochemistry. CXCL17 messenger RNA was expressed in primary tumors at high levels, while it was barely detected in normal colon tissue (p < 0.0001). Similarly, CXCL17 messenger RNA levels were significantly higher in hematoxylin- and eosin-positive (hematoxylin and eosin (+)) lymph nodes compared to hematoxylin- and eosin-negative nodes (p < 0.0001). CXCL17 messenger RNA levels were investigated in lymph nodes grouped according to carcinoembryonic antigen messenger RNA levels: low (–), intermediate (int), and high (+). CXCL17 messenger RNA levels were higher in the carcinoembryonic antigen (int) and carcinoembryonic antigen (+) groups compared to the carcinoembryonic antigen (−) group (p = 0.03 and p < 0.0001, respectively). In lymph nodes of stage III and IV patients, CXCL17 messenger RNA levels correlated with carcinoembryonic antigen messenger RNA levels (p < 0.0001, r = 0.56 and p = 0.0002, r = 0.66, respectively). Staining of consecutive lymph node sections for CXCL17 and carcinoembryonic antigen demonstrated that the same cells expressed both proteins. Altogether, these results indicate that CXCL17 in lymph nodes is expressed by tumor cells. Patients were grouped according to the CXCL17 mRNA levels in the highest lymph node with low levels (−) and high levels (+). CXCL17(+) CC patients showed 2.2 fold increased risk for recurrence (P = 0.03) and decreased mean disease-free survival time of 33 months compared to CXCL17(−) CC patients (P = 0.03). CXCL17(+) carcinoembryonic antigen (int) colon cancer patients showed increased risk for recurrence by 8.3 fold (p = 0.04) and decreased mean disease-free survival time of 46 months compared to CXCL17(−) carcinoembryonic antigen (int) colon cancer patient at follow-up after 12 years (p = 0.02). The presence of tumor cells expressing CXCL17 in regional lymph nodes is a sign of poor prognosis. Analysis of CXCL17 messenger RNA is particularly useful to detect less differentiated colon cancer tumors expressing relatively low carcinoembryonic antigen messenger RNA levels. Thus, CXCL17 messenger RNA in combination with carcinoembryonic antigen messenger RNA may be used as a complementary tool to the hematoxylin and eosin method for detection of poorly differentiated, aggressive tumors." @default.
• W2892013171 created "2018-09-27" @default.
• W2892013171 creator A5003575996 @default.
• W2892013171 creator A5008612449 @default.
• W2892013171 creator A5013075905 @default.
• W2892013171 creator A5029143535 @default.
• W2892013171 creator A5034059060 @default.
• W2892013171 creator A5046916385 @default.
• W2892013171 creator A5054749432 @default.
• W2892013171 creator A5066444789 @default.
• W2892013171 date "2018-08-01" @default.
• W2892013171 modified "2023-10-18" @default.
• W2892013171 title "Lymph node CXCL17 messenger RNA: A new prognostic biomarker for colon cancer" @default.
• W2892013171 cites W1566030615 @default.
• W2892013171 cites W1588649151 @default.
• W2892013171 cites W1669428397 @default.
• W2892013171 cites W1968592882 @default.
• W2892013171 cites W1970666989 @default.
• W2892013171 cites W1971197141 @default.
• W2892013171 cites W1993965603 @default.
• W2892013171 cites W2004883091 @default.
• W2892013171 cites W2007778401 @default.
• W2892013171 cites W2015047172 @default.
• W2892013171 cites W2039032910 @default.
• W2892013171 cites W2042481588 @default.
• W2892013171 cites W2046408597 @default.
• W2892013171 cites W2146614715 @default.
• W2892013171 cites W2157093199 @default.
• W2892013171 cites W2280062403 @default.
• W2892013171 cites W4250676629 @default.
• W2892013171 doi "https://doi.org/10.1177/1010428318799251" @default.
• W2892013171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30198422" @default.
• W2892013171 hasPublicationYear "2018" @default.
• W2892013171 type Work @default.
• W2892013171 sameAs 2892013171 @default.
• W2892013171 citedByCount "13" @default.
• W2892013171 countsByYear W28920131712019 @default.
• W2892013171 countsByYear W28920131712020 @default.
• W2892013171 countsByYear W28920131712021 @default.
• W2892013171 countsByYear W28920131712022 @default.
• W2892013171 countsByYear W28920131712023 @default.
• W2892013171 crossrefType "journal-article" @default.
• W2892013171 hasAuthorship W2892013171A5003575996 @default.
• W2892013171 hasAuthorship W2892013171A5008612449 @default.
• W2892013171 hasAuthorship W2892013171A5013075905 @default.
• W2892013171 hasAuthorship W2892013171A5029143535 @default.
• W2892013171 hasAuthorship W2892013171A5034059060 @default.
• W2892013171 hasAuthorship W2892013171A5046916385 @default.
• W2892013171 hasAuthorship W2892013171A5054749432 @default.
• W2892013171 hasAuthorship W2892013171A5066444789 @default.
• W2892013171 hasBestOaLocation W28920131711 @default.
• W2892013171 hasConcept C104317684 @default.
• W2892013171 hasConcept C105580179 @default.
• W2892013171 hasConcept C121608353 @default.
• W2892013171 hasConcept C125473707 @default.
• W2892013171 hasConcept C126322002 @default.
• W2892013171 hasConcept C142724271 @default.
• W2892013171 hasConcept C156719811 @default.
• W2892013171 hasConcept C204232928 @default.
• W2892013171 hasConcept C2777387746 @default.
• W2892013171 hasConcept C2779013556 @default.
• W2892013171 hasConcept C2779720271 @default.
• W2892013171 hasConcept C2780849966 @default.
• W2892013171 hasConcept C4692481 @default.
• W2892013171 hasConcept C502942594 @default.
• W2892013171 hasConcept C526805850 @default.
• W2892013171 hasConcept C55493867 @default.
• W2892013171 hasConcept C67705224 @default.
• W2892013171 hasConcept C71924100 @default.
• W2892013171 hasConcept C86803240 @default.
• W2892013171 hasConceptScore W2892013171C104317684 @default.
• W2892013171 hasConceptScore W2892013171C105580179 @default.
• W2892013171 hasConceptScore W2892013171C121608353 @default.
• W2892013171 hasConceptScore W2892013171C125473707 @default.
• W2892013171 hasConceptScore W2892013171C126322002 @default.
• W2892013171 hasConceptScore W2892013171C142724271 @default.
• W2892013171 hasConceptScore W2892013171C156719811 @default.
• W2892013171 hasConceptScore W2892013171C204232928 @default.
• W2892013171 hasConceptScore W2892013171C2777387746 @default.
• W2892013171 hasConceptScore W2892013171C2779013556 @default.
• W2892013171 hasConceptScore W2892013171C2779720271 @default.
• W2892013171 hasConceptScore W2892013171C2780849966 @default.
• W2892013171 hasConceptScore W2892013171C4692481 @default.
• W2892013171 hasConceptScore W2892013171C502942594 @default.
• W2892013171 hasConceptScore W2892013171C526805850 @default.
• W2892013171 hasConceptScore W2892013171C55493867 @default.
• W2892013171 hasConceptScore W2892013171C67705224 @default.
• W2892013171 hasConceptScore W2892013171C71924100 @default.
• W2892013171 hasConceptScore W2892013171C86803240 @default.
• W2892013171 hasFunder F4320321615 @default.
• W2892013171 hasFunder F4320322581 @default.
• W2892013171 hasFunder F4320322971 @default.
• W2892013171 hasIssue "9" @default.
• W2892013171 hasLocation W28920131711 @default.
• W2892013171 hasLocation W28920131712 @default.
• W2892013171 hasLocation W28920131713 @default.
• W2892013171 hasLocation W28920131714 @default.
• W2892013171 hasOpenAccess W2892013171 @default.

• next